1. In Vivo
  2. >>Business Strategy

Bristol's Billion-Dollar Ante to Stay in the Cancer Game

Bristol-Myer Squibb's deal to pay up to $2 billion for ImClone System's cancer drug, IMC-C225, should be viewed as a broad strategic move more than a product license. BMS badly needs to shore up its cancer franchise following the expiration of its Taxol patent. It paid dearly for IMC-C225, but unlike some competitors, BMS had no epidermal growth factor receptor-based drug in its pipeline. And because EGFr drugs are widely expected to achieve blockbuster status and be used in combination therapies, BMS needed one as a foundation asset around which to sell its other cancer drugs.

The loss of patent protection last year on paclitaxel (Taxol) has posed the biggest threat to Bristol-Myers Squibb Co. 's leadership position in oncology drugs in over a decade. Never a company reliant on internal R&D, it badly needed to in-license a major late-stage or already-marketed product to sustain its franchise.

Bristol's whopping September deal for ImClone Systems Inc. 's lead cancer product, IMC-C225, should therefore be viewed more as...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business Strategy

Infographic: How Big Pharma Is Scaling Beyond Pilot AI Projects

 
• By David Wild

Pharma leaders are shifting from AI pilots to enterprise-scale deployment, favoring external partnerships for efficiency gains while maintaining tight control over sensitive clinical data.

When VC Steps Back: Finding Alternative Biotech Funding

 
• By Jo Shorthouse

The biotech funding landscape is undergoing a fundamental shift. With traditional VC becoming increasingly cautious and selective, industry executives are exploring new avenues for capital. Conversely, this evolution may ultimately benefit the sector's long-term sustainability.

Podcast: “They Are Able To Keep Their Body”: Medipost On Its Stem Cell Therapy Vision

 
• By Anabel Costa-Ferreira

In Vivo spoke with Edward Ahn, CEO of Medipost, a Korean company that has developed stem cell therapies from cord blood, on how they are working across regulatory markets to provide a novel treatment for degenerative diseases.

Can Italy Shake Off Its Reputation And Become A Premier Hub For Biotech?

 
• By Barnaby Pickering

Leading industry experts have spoken to In Vivo about how investment, a change in mindset and a fresh approach to policy may allow Italy to kick-start its biotech ecosystem.

More from In Vivo

video
Sponsored by:

Meeting the demands of the global biologics market

Lonza is addressing the growing global demand for biologics by utilizing its expert teams and the advanced capabilities of its newly acquired large-scale manufacturing site in Vacaville, California. Joanna McCafferty, Director of Commercial Development, shares more in this brief video. Ask ChatG

Mapping The Power And Potential Of Europe’s Market Access Collaborations

 
• By Leela Barham

Understand who’s influencing access decisions and how pharma can engage strategically across the continent.

Infographic: How Big Pharma Is Scaling Beyond Pilot AI Projects

 
• By David Wild

Pharma leaders are shifting from AI pilots to enterprise-scale deployment, favoring external partnerships for efficiency gains while maintaining tight control over sensitive clinical data.